Publications by authors named "Gregory E Edelstein"

Claim this Profile
V
Virologic characteristics of SARS-CoV-2 infection across evolving Omicron subvariants.
Julie Boucau, Owen T Glover, Caitlin Marino, Gregory E Edelstein, Manish C Choudhary

JCI Insight· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-Neutralization of Distant Coronaviruses Strongly Correlates with Spike S2-Specific Antibodies from Immunocompetent and Immunocompromised Vaccinated SARS-CoV-2-Infected Patients.
Sara V Patel, Brooke M Leeman, Patricia J Botros, Joanna Folta, Dhiman Shahid, Gregory E Edelstein

Vaccines (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral Therapy.
Jessica S Little, Gregory E Edelstein, Zoe Swank, Manish C Choudhary, Ella Borberg

Clin Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 induces persistent transcriptional changes in adipose tissue that are not associated with Long COVID.
Soneida DeLine-Caballero, Kalani Ratnasiri, Heping Chen, Seynt Jiro Sahagun, Uma M Mangalanathan, Gregory E Edelstein

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
Tin Phan, Ruy M Ribeiro, Gregory E Edelstein, Julie Boucau, Rockib Uddin

J Virol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging SARS-CoV-2 Resistance After Antiviral Treatment.
Trevor J Tamura, Manish C Choudhary, Rinki Deo, Fizah Yousuf, Anadela Navarrete Gomez, Gregory E Edelstein

JAMA Netw Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
Tin Phan, Ruy M Ribeiro, Gregory E Edelstein, Julie Boucau, Rockib Uddin

bioRxiv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency.
Yijia Li, Manish C Choudhary, James Regan, Julie Boucau, Anusha Nathan, Gregory E Edelstein

Sci Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Gregory E Edelstein, Julie Boucau, Rockib Uddin, Caitlin Marino, May Y Liew

Ann Intern Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency.
Yijia Li, Manish C Choudhary, James Regan, Julie Boucau, Anusha Nathan, Gregory E Edelstein

medRxiv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
Gregory E Edelstein, Julie Boucau, Rockib Uddin, Caitlin Marino, May Y Liew

medRxiv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis